drugset / Trial / NCT06672237
A Phase 3 Study of NTLA-2001 in ATTRv-PN
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
Timeline
- Start
- 2024-11-22
- Primary completion
- 2027-07
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | nexiguran ziclumeran | Unknown | 55 mg | Intravenous |